ActivBiotics is calling it quits following the failure of its lead therapy. All its assets--which includes a library of 250 small molecules and 800 antibacterial compounds--are going on the auction block this week, with final bids due February 1. The company's lead drug, rifalazil, failed in trials as a new therapy for peripheral arterial disease. And last year the company dumped its plans to go public, citing market conditions. ActivBiotics was founded 11 years ago as Merlin Technologies.
- see the release for more
- read the report from MassHighTech
Related Article:
ActivBiotics, Metaphore sign merger agreement. Report